[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fS1oRzoSAU6WypPzHn7eu0g00ulu1Ovdryqg4JvzT9gY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":34,"rows":41},"National University of Ireland, Galway, Ireland",[4],46,false,8,1,13691,0,42,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Venous Thrombosis",4,{"name":18,"count":19},"Coronary Artery Disease",3,{"name":21,"count":19},"Cardiovascular Diseases",{"name":23,"count":24},"Myocardial Ischemia",2,{"name":26,"count":24},"Coronary Disease",{"name":28,"count":24},"Heart Diseases",{"name":30,"count":24},"Arterial Occlusive Diseases",{"name":32,"count":24},"Vascular Diseases",[],[35,36,37,38,39,40],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[42,73,91,109,127,154,181,199,217,247,265,283],{"intervention":43,"totalTrials":9,"cells":44},"Thiazide or Thiazide-like diuretics",{"EARLY_PHASE1":45,"PHASE1":47,"PHASE2":49,"PHASE3":51,"PHASE4":53,"NA":71},{"trials":46,"activeCount":11},[],{"trials":48,"activeCount":11},[],{"trials":50,"activeCount":11},[],{"trials":52,"activeCount":11},[],{"trials":54,"activeCount":11},[55],{"nctId":56,"briefTitle":57,"status":58,"phases":59,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":64,"interventions":67},"NCT04330300","Coronavirus (COVID-19) ACEi\u002FARB Investigation","SUSPENDED",[39],"2021-07-31","2021-12-01","2020-04-30",2414,[65,66],"Hypertension","COVID-19",[43,68,69,70],"Calcium Channel Blockers","ACE inhibitor","Angiotensin receptor blocker",{"trials":72,"activeCount":11},[],{"intervention":68,"totalTrials":9,"cells":74},{"EARLY_PHASE1":75,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":83,"NA":89},{"trials":76,"activeCount":11},[],{"trials":78,"activeCount":11},[],{"trials":80,"activeCount":11},[],{"trials":82,"activeCount":11},[],{"trials":84,"activeCount":11},[85],{"nctId":56,"briefTitle":57,"status":58,"phases":86,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":87,"interventions":88},[39],[65,66],[43,68,69,70],{"trials":90,"activeCount":11},[],{"intervention":69,"totalTrials":9,"cells":92},{"EARLY_PHASE1":93,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":101,"NA":107},{"trials":94,"activeCount":11},[],{"trials":96,"activeCount":11},[],{"trials":98,"activeCount":11},[],{"trials":100,"activeCount":11},[],{"trials":102,"activeCount":11},[103],{"nctId":56,"briefTitle":57,"status":58,"phases":104,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":105,"interventions":106},[39],[65,66],[43,68,69,70],{"trials":108,"activeCount":11},[],{"intervention":70,"totalTrials":9,"cells":110},{"EARLY_PHASE1":111,"PHASE1":113,"PHASE2":115,"PHASE3":117,"PHASE4":119,"NA":125},{"trials":112,"activeCount":11},[],{"trials":114,"activeCount":11},[],{"trials":116,"activeCount":11},[],{"trials":118,"activeCount":11},[],{"trials":120,"activeCount":11},[121],{"nctId":56,"briefTitle":57,"status":58,"phases":122,"primaryCompletion":60,"completion":61,"start":62,"enrollment":63,"conditions":123,"interventions":124},[39],[65,66],[43,68,69,70],{"trials":126,"activeCount":11},[],{"intervention":128,"totalTrials":9,"cells":129},"Metformin Hydrochloride",{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":150,"NA":152},{"trials":131,"activeCount":11},[],{"trials":133,"activeCount":11},[],{"trials":135,"activeCount":11},[],{"trials":137,"activeCount":11},[138],{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},"NCT02980276","RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects","COMPLETED",[38],"2023-01-12","2023-04-13","2017-06-06",535,[148],"Gestational Diabetes",[128],{"trials":151,"activeCount":11},[],{"trials":153,"activeCount":11},[],{"intervention":155,"totalTrials":9,"cells":156},"20 million hMSCs",{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":173,"PHASE3":175,"PHASE4":177,"NA":179},{"trials":158,"activeCount":11},[],{"trials":160,"activeCount":11},[161],{"nctId":162,"briefTitle":163,"status":141,"phases":164,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"NCT03455335","Autologous Stem Cells for the Treatment of No Option Critical Limb Ischemia",[36],"2019-10-31","2015-03-23",12,[169],"Critical Limb Ischemia",[155,171,172],"40 million hMSCs","80 million hMSCs",{"trials":174,"activeCount":11},[],{"trials":176,"activeCount":11},[],{"trials":178,"activeCount":11},[],{"trials":180,"activeCount":11},[],{"intervention":171,"totalTrials":9,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":191,"PHASE3":193,"PHASE4":195,"NA":197},{"trials":184,"activeCount":11},[],{"trials":186,"activeCount":11},[187],{"nctId":162,"briefTitle":163,"status":141,"phases":188,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":189,"interventions":190},[36],[169],[155,171,172],{"trials":192,"activeCount":11},[],{"trials":194,"activeCount":11},[],{"trials":196,"activeCount":11},[],{"trials":198,"activeCount":11},[],{"intervention":172,"totalTrials":9,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":209,"PHASE3":211,"PHASE4":213,"NA":215},{"trials":202,"activeCount":11},[],{"trials":204,"activeCount":11},[205],{"nctId":162,"briefTitle":163,"status":141,"phases":206,"primaryCompletion":165,"completion":165,"start":166,"enrollment":167,"conditions":207,"interventions":208},[36],[169],[155,171,172],{"trials":210,"activeCount":11},[],{"trials":212,"activeCount":11},[],{"trials":214,"activeCount":11},[],{"trials":216,"activeCount":11},[],{"intervention":218,"totalTrials":9,"cells":219},"Daratumumab",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":239,"PHASE3":241,"PHASE4":243,"NA":245},{"trials":221,"activeCount":11},[],{"trials":223,"activeCount":11},[224],{"nctId":225,"briefTitle":226,"status":227,"phases":228,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},"NCT02955810","Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)","UNKNOWN",[36],"2018-09","2020-11","2016-11",18,[234],"Multiple Myeloma",[218,236,237,238],"Cyclophosphamide","Bortezomib","Dexamethasone",{"trials":240,"activeCount":11},[],{"trials":242,"activeCount":11},[],{"trials":244,"activeCount":11},[],{"trials":246,"activeCount":11},[],{"intervention":236,"totalTrials":9,"cells":248},{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":263},{"trials":250,"activeCount":11},[],{"trials":252,"activeCount":11},[253],{"nctId":225,"briefTitle":226,"status":227,"phases":254,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":255,"interventions":256},[36],[234],[218,236,237,238],{"trials":258,"activeCount":11},[],{"trials":260,"activeCount":11},[],{"trials":262,"activeCount":11},[],{"trials":264,"activeCount":11},[],{"intervention":237,"totalTrials":9,"cells":266},{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":275,"PHASE3":277,"PHASE4":279,"NA":281},{"trials":268,"activeCount":11},[],{"trials":270,"activeCount":11},[271],{"nctId":225,"briefTitle":226,"status":227,"phases":272,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":273,"interventions":274},[36],[234],[218,236,237,238],{"trials":276,"activeCount":11},[],{"trials":278,"activeCount":11},[],{"trials":280,"activeCount":11},[],{"trials":282,"activeCount":11},[],{"intervention":238,"totalTrials":9,"cells":284},{"EARLY_PHASE1":285,"PHASE1":287,"PHASE2":293,"PHASE3":295,"PHASE4":297,"NA":299},{"trials":286,"activeCount":11},[],{"trials":288,"activeCount":11},[289],{"nctId":225,"briefTitle":226,"status":227,"phases":290,"primaryCompletion":229,"completion":230,"start":231,"enrollment":232,"conditions":291,"interventions":292},[36],[234],[218,236,237,238],{"trials":294,"activeCount":11},[],{"trials":296,"activeCount":11},[],{"trials":298,"activeCount":11},[],{"trials":300,"activeCount":11},[]]